GlaxoSmithKline and Johnson & Johnson will become pharma partnering for increasing production of an Ebola vaccine, with an aim to produce at least 1 million doses next year. Read the full story

The University of Texas MD Anderson Cancer Center announced it formed a research alliance with GlaxoSmithKline to strengthen its efforts in advancing therapies that train the body's immune system to combat cancer. Read the full story

GlaxoSmithKline will acquire a stake in the Japanese subsidiary of Aspen Pharmacare Holdings as part of an alliance to boost commercial operations in the Asian country. Read the full story

Morphosys is a leading biotechnology developing therapeutic antibodies for a range of different indications. Read the full story

Several companies, including Mylan , have submitted a second round of bidding for a portfolio of older GlaxoSmithKline drugs.   Read the full story

Novartis signs pharma deal with GlaxoSmithKline and Eli Lilly for exchange of oncology, vaccine and animal health business units.  Read the full story

Merck enters into a pharma licensing deal with GSK for evaluating combination therapy for renal cell carcinoma. Read the full story

In dealtalk, Blackstone and Lion Capital are to make a joint bid for Lucozade and Ribena from big pharma Roche. Read the full story

Renaissance Acquisition Holdings and GlaxoSmithKline, a big pharma company  have entered into pharma licensing deals agreement giving Renaissance the rights in the USA to manufacture, market and sell six dermatology and three anti-viral products from GSK Read the full story

MorphoSys have entered into a global pharma licensing agreement with GlaxoSmithKline to develop and commercialize MOR103 Read the full story